Success Metrics

Active Trials
15(83%)

Phase Distribution

Ph phase_1
8
44%
Ph phase_2
6
33%
Ph phase_3
4
22%

Phase Distribution

8

Early Stage

6

Mid Stage

4

Late Stage

Phase Distribution18 total trials
Phase 1Safety & dosage
8(44.4%)
Phase 2Efficacy & side effects
6(33.3%)
Phase 3Large-scale testing
4(22.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

15

trials recruiting

Total Trials

18

all time

Status Distribution
Active(18)

Detailed Status

Recruiting14
Not yet recruiting3
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
18
Active
15
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 18 (44.4%)
Phase 26 (33.3%)
Phase 34 (22.2%)

Trials by Status

recruiting1478%
active_not_recruiting16%
not_yet_recruiting317%

Recent Activity

Clinical Trials (18)

Showing 18 of 18 trials
NCT06369467Phase 1

Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy

Recruiting
NCT07009899Phase 2

BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM)

Not Yet Recruiting
NCT06292780Phase 1

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

Recruiting
NCT07222761Phase 3

A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Recruiting
NCT03761108Phase 1

Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

Recruiting
NCT07455851Phase 1

A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma

Recruiting
NCT06669247Phase 1

A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma

Recruiting
NCT05955508Phase 2

A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma

Active Not Recruiting
NCT06140524Phase 2

A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

Recruiting
NCT07181941Phase 1

Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma

Recruiting
NCT06932562Phase 3

A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant

Recruiting
NCT05828511Phase 1

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

Recruiting
NCT07393282Phase 3

A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

Not Yet Recruiting
NCT05730036Phase 3

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

Recruiting
NCT07428369Phase 2

A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)

Not Yet Recruiting
NCT05137054Phase 1

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Recruiting
NCT06910124Phase 2

Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse

Recruiting
NCT06376526Phase 2

IMMUNOPLANT for Newly Diagnosed Multiple Myeloma

Recruiting

All 18 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
18